Special Programme for Research by Lisa Schwarb Foreword
Snippets of 
achievement
... THE PAST ILLUMINATING THE FUTURE ...
                             UNDP/World Bank/WHO  
Special Programme for Research and Training in Tropical Diseases (TDR)Snippets of 
achievement
17 examples from the past illuminating the future
UNDP/World Bank/WHO 
Special Programme for Research 
and Training in Tropical Diseases (TDR)TDR/GEN/01.1
This document is not a formal publication of the World Health Organization (WHO), and all rights are
reserved by the Organization.The document may, however, be freely reviewed, abstracted, reproduced or
translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes.
The views expressed in documents by named authors, are solely the responsibility of those authors.
© TDR 2001
Editor: Nina Mattock
Concept and design:Andy Crump and Lisa SchwarbForeword
TDR’s new strategy represents an evolution of a 
very dynamic programme. It builds on 25 years of
success in research and training in tropical diseases.
The document at hand is an attempt to illustrate the
strategy by providing examples from the past. The
examples have been selected to highlight TDR’s range
of expertise, its global leadership in the field, and
its unique capability for building and maintaining
partnerships, involving public and private sectors, and
developing and developed countries alike. For a full
account of achievements the reader is referred to the
TDR biennial programme reports.
The design and layout of the Snippets of Achievement
will hopefully appeal to a wide range of audiences
including more outside the circles of the Programme’s
usual stakeholders.
Carlos M. Morel, 
Director, TDR
Erik Blas, 
Programme Manager, TDRBackground 
TDR supports research to find solutions to public health problems related to neglected infectious
diseases that affect poor and marginalized populations.The Programme specifically focuses on 
ten tropical diseases: malaria, tuberculosis, schistosomiasis, lymphatic filariasis, onchocerciasis, leish-
maniasis,Chagas disease,African trypanosomiasis,leprosy,and dengue.Some of these diseases are
the targets for major global efforts of control.The others are also causing major public health
problems and are targets for regional and national control efforts, as they affect different parts of
the world in different ways, depending on social, economic, political, and ecological factors.
Appropriate means for control often do not exist, are not accessible for those in need, or are
increasingly becoming ineffective, for example, due to drug resistance.
A major determinant for the burden of disease is poverty.For the TDR group of diseases,the gap
between the world's 20% poorest population groups and the 20% richest, in terms of death, is
wide. If the world’s poor were to suffer the same death rates (from TDR diseases) as the world’s
rich, then the gl;obal number of deaths would be reduced markedly - by 97.5% from tuberculo-
sis, by 99.6% from malaria, and by 99.9% from the other TDR diseases. Only diarrhoeal diseases,
childhood cluster diseases, and maternal conditions come close to producing the same excess
death amongst poor populations as do the TDR diseases.
In addition to the direct suffering caused by tropical diseases,they also adversely affect the socioe-
conomic development of poor countries and populations. For example, studies have shown that
in Kenya, 11% of primary school days are lost to malaria, with the disease also causing losses of
2-6% of the nation’s GDP. In Nigeria, 1-5% of the country’s GDP is lost due to malaria. In the
Philippines, schistosomiasis infection causes annual losses of 41.6 workdays, compared to 3.8 lost
days in control groups.
Strategy
TDR uses research to find solutions to public health problems related to neglected infectious dis-
eases that affect the poor and disadvantaged.This requires not only close collaboration with dis-
ease control programmes and ministries of health, but also with researchers and product devel-
opers from industrialized and developing countries. It further requires strong technical and man-
agerial systems and expertise, in addition to sufficient and reliable flows of appropriate resources.
Value-based organization
TDR is a value-based organization that draws its values from the international community.
TDR’s specific organizational beliefs and values are:
• Good health is an essential foundation for social and economic development and access to
basic health care is a human right.“ The enjoyment of the highest attainable standard of health
is a fundamental human right.”
• Social, economic and gender inequities are major impediments to improvements in health 
status.• Research and development of means to combat disease and improve health must adhere to
internationally accepted ethical principles.
• Knowledge is a crucial element in health improvement, and the attainment of self-reliance in
research and development in disease endemic countries is key to sustainability.
• Closing of the global gap in research and product development between the rich and poor
requires collaboration and partnership between the public and private sectors and involvement
of research,planning and implementing agencies at international,national and local levels as well
as the targeted populations.
• It is essential for the successful functioning of TDR that it retains scientific independence, oper-
ational transparency and special programme status within the UN system.
• As an organization of the international community, TDR values professional competence,
together with gender and geographical balance in staffing, committee membership, and partic-
ipation in research and product development.
Goals
TDR contributes to the attainment of the following goals:
• To alleviate inequity and poverty and foster social and economic development in endemic
countries through reduction of mortality,morbidity and disability caused by neglected infectious
diseases which affect poor and marginalized populations.
• To increase research self-reliance in endemic countries for identifying needs and developing
solutions to public health problems caused by neglected infectious diseases.
Objectives
The objectives are considered within TDR’s managerial control.Their attainment is the collective
responsibility of the whole Programme across diseases, functions, and categories of staff. The
attainment of the objectives is the basis on which the strategy will be reviewed and evaluated.
• To improve existing and develop new approaches for preventing, diagnosing, treating, and con-
trolling neglected infectious diseases which are applicable, acceptable, and affordable by devel-
oping endemic countries, which can be readily integrated into the health services of these
countries, and which focus on the health problems of the poor.
• To  strengthen the capacity of developing endemic countries to undertake the research required
for developing and implementing these new and improved disease control approaches.
In-house expertise
TDR has a full range of in-house scientific expertise, from basic biomedical and social science,
through product development, to clinical field research, capacity building, and communication, etc.
The breadth and depth of this expertise in the field of tropical diseases is unparalleled.
TDR has a reputation for efficiency, stability, and transparency – it is a safe investment.The pro-
gramme has developed and continues to strengthen its capacity to manage, in an efficient way, a
large number of projects which are implemented in partnerships with outside experts through-
out the world.A Special Programme
As a special co-sponsored programme,TDR has the advantage of being housed within the UN sys-
tem, while at the same time, donors and clients have direct managerial authority through the Joint
Coordinating Board.
How does TDR work and what does it produce?
TDR acts as a catalyst by facilitating R&D agenda and priority setting, funding projects, and provid-
ing service in the form of technical guidance, capacity building, and brokerage to bring partners
together who have the comparative advantages required to make the end-product become a real-
ity.TDR is rarely the owner of the final product, nor is it normally the sole contributor to the
process resulting in the product.That is, the products materialize through the joint efforts of many
partners,including academia,industry,public and private institutions,and donors from developing and
developed countries.
TDR has a unique set of operational capabilities,which allows it to bring together the world’s lead-
ing researchers and product developers from the public and private sectors, from developing and
developed countries, to address public health problems related to neglected infectious diseases.
TDR’s end-users are the poor and marginalized populations in developing endemic countries who
do not have access to appropriate and cost-effective means to prevent and treat their neglected
infectious diseases.TDR reaches the end-users through its clients in public and private health sys-
tems and national and international disease control programmes.
TDR’s end-products are solutions to public health problems.These will emerge from knowledge gen-
erated by research, and from developing, testing, and validating tools, intervention methods, and
implementation strategies.The products will range from environmental, through population and sys-
tems based interventions, to products aimed at diagnosing and treating diseases in the individual.
These products must be applicable, acceptable, and affordable by developing endemic countries,
easy to integrate into the health services of these countries, and must focus on the health prob-
lems of the poor.
Expected Results 
The snippets of achievement in this document are organized according to the six technical expect-
ed results areas of the strategy:
A. New basic knowledge
New basic knowledge about the biological,social,economic,health systems and behavioural deter-
minants, and other factors of importance for effective control of neglected infectious 
diseases.
• Onchocercal skin disease
• The transformation of a mosquito
• Parasite genomeB. New and improved tools
New and improved tools for use in infectious disease prevention and control, e.g. drugs, vaccines,
diagnostics, epidemiological tools, environmental tools, etc.
• Multidrug therapy for leprosy (MDT)
• New drugs brought to registration
• Rapid mapping for onchocerciasis
C. New and improved intervention methods
New and improved methods for applying existing and new tools at the clinic and community levels.
• Vector control for Chagas disease
• Bednets
• Unit-dose packaging of antimalarials
D. New and improved policies, prevention and control strategies
New and improved policies for large-scale implementation of existing and new prevention and
control strategies.
• Community-Directed Treatment (ComDT)
• Getting drugs into wide control use
E. Partnerships and capacity building
Building partnerships throughout the world and increasing the involvement of developing coun-
try researchers and product developers by providing support for building research capacity.
• Partnerships in science
• Building research capacity in least developed countries
• Technology transfer
• Knowledge and research capacity for schistosomiasis control in China
F. Dissemination of information, guidelines, instruments and advice
Provide technical information and advice and publish research guidelines and instruments.
• Internet communication
• Guidelines to good practicesSnippets of 
achievement
Examples from the past illuminating the futureOnchocerciasis, 
also known as river
blindness, has
plagued millions,
especially in Africa,
for centuries. The
common name 
portrays the common
perception of the 
disease and its public
health impact – it 
causes severe eye 
problems including
permanent blindness,
and shortens life
expectancy by up 
to 15 years. 
But in 1990, another
impact of this disease
became known.
NEW BASIC 
Why did TDR become involved?
Onchocercal skin disease Onchocercal skin disease
Prior to 1990, the social implica-
tions and cultural aspects of on-
chocercal skin disease had been
totally neglected,especially where
women were concerned. For ex-
ample, in areas of Africa where
onchocercal skin disease is com-
monly found, the beauty of the
skin is culturally and socially ex-
tremely important, so the impact
of the disease is exacerbated. In
1989,TDR decided to take a com-
pletely new approach and initiate
work on the socioeconomic im-
pact of the skin disease.This had
not been done before, and no
other agency was working in this
field. In its pioneering work,TDR
brought together social scientists
and biomedical scientists to begin
exploring hitherto neglected as-
pects of this disease.
Introduction
In 1990, the devastating impact of the skin disease accom-
panying infection was recognized and began to be quanti-
fied. Onchocercal dermatitis causes a variety of problems,
mainly as a result of the incessant and unbearable itching
that arises from infection and leads to scratching, which in
turn leads to bleeding and ulceration of the skin, and often
to secondary infection. Disfiguring skin lesions and alter-
ations of skin pigmentation also arise, while rashes, joint
and bone pain, headache and fatigue are commonplace. The
disease causes lost work and productivity, and schoolchild-
ren’s education suffers due to distraction in class caused by
the constant itching. It is estimated that 60% of disability
adjusted life years (DALYs) lost due to onchocerciasis can be
attributed to skin disease. In 1990, of an estimated 15 mil-
lion people with onchocerciasis living in Africa, 8-9 million
lived in areas associated with severe skin disease and 6-7
million in areas associated with blindness. 
Onchocercal dermatitis is now recognized as a major health
problem. As well, it carries with it a severe social stigma,
compounding the pain and suffering that those infected
with the disease already have to live with.  KNOWLEDGE
TDR played a leading and unique
role, opening the door for scien-
tists, agencies and institutions to
examine and expose other as-
pects and impacts of diseases be-
yond the usual biomedical ones.
TDR initiated and supported
studies in communities to uncov-
er the underlying feelings and
concerns of individuals regarding
onchodermal dermatitis.Affected
people worried that the skin dis-
ease had an effect on their ability
to interact socially, and others
complained of being afraid to dis-
close their disease because they
were embarrassed by having con-
tracted the disease and feared be-
ing ostracized.Villagers were up-
set by the intensive itching, and
cited fatigue and insomnia as se-
rious concerns,also revealing that
1 in 3 of them were suffering
from low self-esteem problems
associated with the disease and
the social isolation that resulted.
A further 33% believed they
would never marry because of
the social stigma surrounding the
disease, while 1-2% of the popu-
lation had considered suicide as a
direct result of onchocerciasis.
Children were at least twice as
likely to drop out of school if the
head of their household suffered
from the illness.
TDR galvanized governments,
control programmes, other inter-
national agencies including the
TDR co-sponsors, researchers
and public health workers. It
achieved this by mobilizing and
partially funding an international
network of researchers, institu-
tions and donor agencies, mostly
engaging cross-disciplinary groups
that had never previously worked
together.
The work pioneered by TDR is
now bearing fruit in many other
areas and diseases. For example,
work is being carried out on the
social stigma attached to infection
with leprosy and lymphatic filaria-
sis, and on a wide variety of psy-
chosocial,socioeconomic and be-
havioural aspects of TDR target
diseases.
The impact of TDR’s work has
been immense. Firstly, the work
validated the extent and severity
of the skin disease problem,
creating awareness of its scale and
encouraging the involvement of
players from governmental,
NGO, industrial, academic and
other communities. It significantly
changed the perception and ac-
tions of donor-driven agencies
and disease control activities.
Moreover, the gender aspects 
and differences in how diseases
affect people were brought to the
fore.With the advent of the safe
and effective drug, ivermectin,
to treat onchocercal infection,
the scope for eliminating the 
disease became obvious. The
work on onchocerciasis skin dis-
ease contributed to the ground-
work for plans,by the African Pro-
gramme for Onchocerciasis 
Control (APOC),to eliminate on-
chocerciasis based on distribution
of ivermectin. Furthermore, in-
creased knowledge and aware-
ness of onchocercal skin disease
has made it easier for health
workers to engage affected com-
munities in the single-dose, annu-
al treatment programmes,and get
their commitment to carry out
and pay for the treatment them-
selves.
What were the results?
What was TDR’s role?TDR’s interest in 
transformation of 
the malaria mosquito
began in 1991, 
when the vision of 
a mosquito unable 
to transmit malaria
began to take shape. 
Why did TDR become involved?
TDR engaged global expertise
from a variety of disciplines and
stimulated debate on the poten-
tial of transformed mosquitos. In
1991, 36 specialists were brought
together by TDR, the Wellcome
Trust and the MacArthur Foun-
dation to discuss promising re-
search lines in this new approach
to mosquito control.
Genetically-manipulated 
mosquito larvae fluoresce 
when exposed to UV light.
TDR has a number of compara-
tive advantages, when compared
with other research funding agen-
cies,which mean it is in a position
to orchestrate this visionary
work. One advantage is that TDR
has an international research net-
work and a global vantage point
from which to identify unmet re-
search needs and to plan and car-
ry through international research
programmes which uniquely fill
those needs. TDR was able to
bring the world’s best minds to
What was TDR’s role?  
Introduction
To date, the only effective control programmes for malaria
have been based on control of its vector, the mosquito, but
increasing resistance to insecticides, combined with their
cost and detrimental environmental impact, has led to the
search for new ways of controlling the vector. In 1994, TDR
set up the Strategic Research Molecular Entomology pro-
gramme to develop new approaches to mosquito control.
Using the powerful techniques of molecular biology, the
long-term goal is to replace mosquito vectors in the wild
with mosquito populations that are unable to transmit
malaria parasites.
In 2000, a malaria transmitting species of mosquito was
transformed through the insertion of a gene which makes
them glow green when excited with ultraviolet light. This
green fluorescence gene is used as a model gene and might,
at a later stage, be replaced by genes which inhibit parasite
development. The insertion of the green fluorescence gene
was a breakthrough, although there is still a long way to go
- a projected 10 years. Potentially the most problematic step
has yet to be overcome - driving transformed mosquitos, car-
rying genes that prevent development of the malaria parasite
in them, into wild populations of mosquitos, after careful
assessment of the risks and consequences of such an action.
bear on the problem of trans-
forming the mosquito. Another
advantage is that, owing to its in-
ternational backing and base,TDR
has the organizational and finan-
cial staying power to see long-
term projects through to com-
pletion. And transforming the
mosquito was projected to take
up to 20 years to achieve.
Transformation of a mosquito Transformation of a mosquito
NEW BASIC Three main areas of research
were established. Firstly, to iden-
tify parasite-inhibiting genes, and
key molecules in mosquitos es-
sential for continued develop-
ment of the parasite.This will pro-
vide potential target genes and
molecules that can be introduced
into receptive mosquito strains to
make them refractory to malaria.
The second line of research was
to develop genetic and molecular
tools needed to insert selected
genes into the mosquito genome,
i.e. to transform the mosquito, as
was first achieved in 2000. The
third goal was to develop mech-
anisms for driving selected genes
into natural populations of mos-
quitos, including identifying genes
affecting the mosquito’s choice of
host (man or animal).
TDR mobilized a broad range of
scientists working in relevant fields
of genetics,biochemistry and mo-
lecular biology,inviting them to be
partners of international net-
works. Over 100 projects in 19
countries have been supported.
This collaboration and open in-
formation exchange produced
excellent results, confirming the
feasibility of this innovative ap-
proach to malaria control.
Although it was known that the
ultimate goals would take at least
10-20 years to fully realize,the in-
termediate results, the scientific
advances, are significant and rele-
vant and proving of immediate
practical use in areas such as tax-
onomy and epidemiology. Some
of the results so far are described
below.
In understanding the molecular
basis of mosquito resistance to
the malaria parasite, major gene
loci have been identified where
genes responsible for disrupting
parasite development in the
mosquito are located (these
genes later to be transferred to
susceptible mosquitos).The factor
responsible, in susceptible mos-
quitos, for activating the gametes,
an early stage of the parasites life
cycle, was discovered to be xan-
thurenic acid.A number of possi-
ble receptors, such as enzymes,
on the surfaces of mosquito cells,
that the parasite recognizes be-
fore it invades the cell, have been
distinguished. A new cell type –
Ross cells – was discovered which
the parasite ookinete stage
prefers to invade after crossing
the midgut wall.More than 20 im-
mune response genes (proteases,
protease inhibitors, transcription
factors) have been documented
from Anopheles gambiae mosqui-
tos. An international effort in
Anopheles genomics research has
been initiated (in 2000) as a new
tool for improved understanding
and control of malaria parasite
development in the mosquito.
In developing genetic and molec-
ular tools for engineering a mos-
quito that is resistant to malaria,
the genetic transformation sys-
tem described in 2000 was for
Anopheles stephensi, one of the
major carriers of malaria in urban
areas of the Indian subcontinent.
Use of this system, and its appli-
cation to the main vector of hu-
man malaria in Africa, An. gambi-
ae,will speed up understanding of
the physiology of the mosquito
carriers of the disease and their
interaction with the malaria para-
site, and could lead, ultimately, to
the replacement of wild mosqui-
to populations with strains of
mosquito that cannot transmit
malaria.
In order to develop methods to
spread selected genes in wild
mosquito populations, scientists
are developing a thorough un-
derstanding of mosquito popula-
tion dynamics, and mosquito
host-finding behaviour. Possible
driving forces have been de-
scribed (e.g. ability of transpos-
able elements to spread through
natural populations). New field
data on the population structure
of An.gambiae,from studies look-
ing at the amount of genetic vari-
ation between populations, indi-
cate the existence of a historical
or present-day barrier to gene
flow of this species,the major vec-
tor in Africa.These data are im-
portant for introducing and
spreading foreign genes into wild
vector populations. Through
cross-breeding of man-biting
species with animal-biting species
of mosquito, proteins and genes
thought to be involved in recog-
nizing human odours have been
identified, and cloning and initial
characterization of several classes
of these olfactory genes in An.
gambiae have been performed.
Of course, numerous and impor-
tant scientific, ethical, safety and
regulatory issues will have to be
addressed before such a strategy
could be used to control a vec-
tor-borne disease.
What were the results?
 KNOWLEDGEDespite the advances
of modern medicine,
the chronic illness, 
disfigurement and
death that can result
from parasitic 
infection still threaten
the majority of the
global population 
and retard economic
development. 
Why did TDR become involved?
Widespread and improper use of
the few treatments and vector
control measures that were once
cheap, effective, and easy to ad-
minister, has resulted in the ap-
pearance and spread of resistant
parasites and vectors.Even where
drug resistance is not yet a seri-
ous problem, available treatments
may require long-term drug ad-
ministration and/or hospitaliza-
tion, involve regimens that have
not been standardized, or use
compounds that are sub-curative
or invoke severe side-effects. In
the long term, vaccines are likely
to make a major impact but
progress is impeded by factors
such as antigenic switching, muta-
tion, diversity, autoimmune stimu-
lation and poor antigenicity, such
that no vaccine is yet available for
any parasitic disease.
Rationally designed strategies,
based on an understanding of:
how parasites develop, survive,
and reproduce in their different
hosts; parasite-host and parasite-
immune system interactions; and
factors that determine behaviour,
pathogenicity, drug resistance and
antigenic variation, represent the
only practical approach to identi-
fying new therapies. Sequencing
and understanding those parts of
the genome that encode this in-
formation are key to develop-
ment of the strategies. However,
most large-scale biotechnology
initiatives involving sequencing
and mapping are conceived and
led by scientists in developed
countries.TDR represents one of
the few opportunities for scien-
tists from disease endemic coun-
tries to participate and collabo-
rate in long-term, far-reaching
projects and to acquire the ex-
pertise necessary to exploit ad-
vances in biotechnology.
Introduction
For most parasitic diseases, current therapy often leaves
much to be desired in terms of administration, regimen, tox-
icity, and effectiveness. Potential vaccines are a long way
from market. Our best prospects for identifying new targets
for drugs, vaccines, and diagnostics, and for dissecting the
biological basis of drug resistance, antigenic diversity, infec-
tivity and pathology, lie in analysing and understanding the
parasite genomes. International genome mapping, sequenc-
ing and gene discovery initiatives are under way for a vari-
ety of protozoan and helminth parasites.
TDR has played an important role in the generation of knowl-
edge about the genomes of the parasites that cause African
trypanosomiasis, Chagas disease, leishmaniasis, schistoso-
miasis, and lymphatic filariasis, and is now focusing on pro-
viding capacity to utilize the parasite genome data and on
supporting developments in applied genomics and bioinfor-
matics.
Parasite genome Parasite genome
NEW BASIC  Genome projects break the
mould of conventional scientific
practice by being collaborative ef-
forts performed with a service
function in mind and with the
wish to disseminate data as wide-
ly as possible.As an international-
ly recognized lead organization in
tropical disease research, TDR
was in a unique situation to facil-
itate and support the creation of
international collaborative net-
works.TDR's unique position pro-
vided an umbrella for convening
international experts and giving
scientists from disease endemic
countries the opportunity to par-
ticipate. The Special Programme
status of TDR also provided the
opportunity for developing part-
nerships with other agencies and
institutions to facilitate making the
information available in public
databases.TDR's convening posi-
tion also facilitated a forum for
presentation and discussion of
progress reports - a model that
has become standard procedure
for consortium approaches in
genome projects.
As the work progresses and en-
ters into the next phase – the
post-genomic phase - TDR’s role
will increasingly be to strengthen
the capability of researchers from
disease endemic countries and in-
volve them in collaboration with
the genome networks in order to
exploit the data generated by the
genome projects in developing
new tools for managing the dis-
eases. TDR efforts will now focus
on facilitating the acquisition of
expertise in bioinformatics and
applied genomics by diseases en-
demic country scientists. TDR's
continued support for the
genome networks makes it pos-
sible to organize international
training programmes for transfer
and impact of these technologies
in disease endemic countries.
Parasite genome discovery has
been hugely successful and has
resulted in a logarithmic increase
in the catalogue of known para-
site sequences. The parasite
genome projects are generating
large amounts of data in diverse
forms.These data are of wide in-
terest as they pertain to groups
of organisms that are traditional-
ly under-researched.All the para-
site genome databases are in the
public domain, available both
through the Internet and for lo-
cal installation. Therefore, ‘post-
genomic’ investigations that ex-
ploit the databases for functional
analysis provide ideal opportuni-
ties for researchers from disease
endemic countries to be at the
cutting edge in this field of re-
search, without being disadvan-
taged by poor infrastructures.The
coming years are likely to see
huge improvements in technolo-
gy that will transform molecular
biology from an analytical science
into a discipline of  structure and
functional analysis, and into a
powerful resource for in vivo ma-
nipulation in order to identify
new targets for the development
of diagnostics tests, drugs and
vaccines.
What were the results?
TDR’s role
“The Schistosoma, Brugia malayi
(as model filarial nematode),
Trypanosoma brucei, T. cruzi and
Leishmania initiatives fall within
the UNDP/World Bank/WHO Special
Programme for Research and
Training in Tropical Diseases. TDR
resources are extremely limited 
and its funding is largely ‘pump-
priming’ to facilitate development 
of resources, strategies and 
collaborations to support applica-
tions to national or international
agencies for larger-scale projects.
This ‘pump-priming’ is beginning 
to bear fruit, with the Leishmania 
and T. brucei genome initiatives
recently attracting multi-million 
dollar support”1 
Parasite genome 
initiative web sites:
Leishmania network:
www.ebi.ac.uk/parasites/leish.html
Trypanosoma brucei network: 
parsun1.path.com.ac.uk/
Trypanosoma cruzi network:
www.dbbm.fiocruz.br/
genome/tcruzi.html
Schistosoma genome network:
www.nhm.ac.uk/hosted_sites/
schisto/
Filarial network:
helios.bto.ed.ac.uk/mbx/fgn/
filgen1.html
Coordinating sites
Parasite genome:
www.ebi.ac.uk/parasites/
parasite-genome.html
WHO-TDR parasite genome 
committee: www.who.ch/tdr/
workplan/genome.html
Parasite genome mailing list
archive: www.mailbase.ac.uk/
lists-p-t/parasite-genome
 KNOWLEDGEA researcher in
Bombay who inter-
viewed women on what
they considered to be
the most difficult part
of coping with leprosy,
found that ‘it was
touch more than 
anything, that women
longed for, and the 
loss of this intimate
right symbolized such 
isolation and 
rejection.’ 
Why did TDR become involved?
When TDR was founded in 1975,
it took a leading role in leprosy
research, strongly based on the
promises offered by molecular bi-
ology, especially with a view to
providing new control tools. By
the early 1970s, drug treatments
were becoming ineffective.Ther-
apy with the cheap and readily-
available drug dapsone was inter-
minably long and drug resistance
was becoming increasingly evi-
dent. Leprosy therapy meant
years of continuous treatment,of-
ten for life, and relapses were a
continual threat. Of the other
drugs used, clofazimine could
cause dark discoloration of the
skin, thus increasing the severe
trauma of those who already had
to live with the unbearable social
stigma and sense of isolation that
leprosy induces.Another drug, ri-
fampicin, already used extensively
in the treatment of tuberculosis,
had rapid bactericidal effect on
Mycobacterium leprae (the mi-
croorganism which causes lep-
rosy) but was extremely expen-
sive and produced adverse side-
effects. Even as the programme
was being established, TDR’s
founders recognized the failure of
mono-therapy and set the two-
fold goal of improving drug effec-
tiveness and reducing the dura-
tion of drug treatments.
Introduction
Leprosy can be traced back at least 2500 years, making it
one of the oldest recorded diseases afflicting humans. A
chronic disease caused by a bacillus, which can be transmit-
ted via droplets from the nose and mouth of infected peo-
ple, it affects the skin and can cause nerve damage, eventu-
ally leading to hideous deformities. It has struck fear and
loathing in the hearts of communities down through the
ages, with millions being cast out, banished to leper
colonies, often disowned by their own families and loved
ones. Poverty is a significant factor in preventing control of
this dreaded disease. Ignorance of the disease has also
played a major role. However, administering a cocktail of dif-
ferent drugs in specific dosages – multidrug therapy, or MDT
–  can cure leprosy and should lead to its elimination. 
MDT for leprosy MDT for leprosy
NEW AND In close collaboration with the
WHO leprosy programme, TDR
orchestrated and funded work on
leprosy drugs, mapping dapsone
resistance (a long and arduous
process) to establish the scale of
the problem. TDR worked with
research groups,scientists,nation-
al leprosy programmes and
NGOs, coordinating large-scale
drug combination trials in India
and Africa and seeing them
through to completion. As an in-
dependent and trusted broker,
TDR could organize and oversee
field trials in disease-endemic
countries. It could also persuade
pharmaceutical companies to en-
gage in trials of their drugs along-
side those from other manufac-
turers, stimulate and engage sci-
entists, researchers and govern-
ments. And it could provide fi-
nance and mobilize further re-
sources, following through on
products that may not prove
commercially profitable.
The work revealed that combina-
tion therapy was extremely effec-
tive and, in 1981, WHO recom-
mended the use of multidrug
therapy (MDT) for the treatment
of leprosy, based primarily on
TDR’s findings.TDR continued the
research to both improve the
drug combinations being used
and reduce treatment durations,
working closely with the WHO
leprosy programme. This contin-
ued commitment resulted in var-
ious other drugs being investigat-
ed, and the so-called ‘ROM’ com-
binations (comprising rifampicin,
ofloxacin and minocycline) were
developed and introduced as ‘re-
fined products’ in 1997, some 16
years after MDT had become
WHO recommended therapy.
Other new drug regimens are still
under trial.The hope is to reduce
MDT treatment duration to
weeks, or possibly even to days.
The work of TDR and its partners
has brought huge returns. Drug
combinations produced a highly
effective treatment strategy, and
the leprosy bacillus has not de-
veloped any resistance to MDT.
Since the introduction of MDT,
there has been a dramatic reduc-
tion in prevalence of leprosy,from
5.4 million registered patients in
1985 to around 0.75 million at the
beginning of 2000.The disease has
been eliminated from 98 coun-
tries and the global leprosy elim-
ination targets will be met in
2001. Early detection and treat-
ment with MDT has prevented
some 3-4 million people from be-
ing disabled. However, there is a
need to detect and treat about
2.5 million new cases over the
next five years to achieve elimi-
nation. The Japanese-based Nip-
pon Foundation has played a lead-
ing role in bringing the elimination
of leprosy closer to fruition, to-
gether with the Novartis phar-
maceutical company and Novar-
tis Foundation for Sustainable De-
velopment, which has also made
a major contribution in providing
MDT free of charge to all leprosy
patients.Along with TDR,they are
crucial players in ensuring that re-
search on the transmission and in-
cidence of leprosy, on improved
methods of detection and on pre-
vention and management of
nerve damage,continues and that
MDT is widely employed to attain
the goal of eliminating leprosy and
ridding the world of one of its
most dreaded diseases.
What were the results?
What was TDR’s role?
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 IMPROVED TOOLSAccording to an 
analysis by Pécoul 
et. al.1 of the 1233 new
drugs identified as
reaching the market
between 1975-97, only
13 were approved
specifically for tropical
diseases. Of these 13, 
six were developed with
TDR support.
TDR’s role can begin anywhere
between the discovery of a new
therapeutic target for compound
identification and the last stages of
its clinical development and reg-
istration.TDR brings partners to-
gether, providing strategic funding
and technical support,and organ-
TDR’s end-products are solutions
to public health problems caused
by neglected infectious diseases
affecting poor and marginalized
populations. Drugs constitute
many of these solutions – drugs
are the mainstay of most public
health programmes aimed at re-
ducing mortality and morbidity in
the developing world.
The centrepiece of TDR’s opera-
tional capability is its ability to
bring together the public and pri-
vate sectors, industry and acade-
mia, developed and developing
countries, in partnerships that
What was TDR’s role?
Introduction
The problem is market failure. Drug research and develop-
ment is so costly in terms of time and money, that, in the
face of counterfeit drugs and circumvention of patent rights
in some countries, together with non-solvent populations,
there are no market incentives to motivate the pharmaceu-
tical industry. Unless commercial returns will be good and/or
risks reduced, the industry (with few exceptions) will not
invest time and resources in drugs for tropical diseases. 
Six of the 13 drugs identified by Pécoul et. al. – artemether,
mefloquine, eflornithine, albendazole, ivermectin, and lipid
associated amphotericin – were developed with TDR help.
Other drugs which have received TDR input and are now reg-
istered for use include: mefloquine + pyrimethamine combi-
nation, and artemotil for malaria. Also, TDR supported trials
of benznidazole for early chronic Chagas disease, praziquan-
tel combinations for schistosomiasis, and albendazole 
combinations for lymphatic filariasis. In total, TDR has
helped bring 13 new chemical entities to registration or rec-
ommendation for use in the control of tropical diseases, and
others are in the pipeline. 
exploit the comparative advan-
tages of each partner.By doing so,
both the costs and the risks in-
volved can be significantly re-
duced and the relevance of the
outcome ensured.TDR not only
provides direct funding, but also
facilitates transfer of knowledge
and technology, and provides di-
rect technical support to all
stages of the processes involved
in bringing new drugs to registra-
tion or recommendation for use
for disease control programmes.
New drugs brought 
to registration
New drugs brought 
to registration
Why did TDR become involved?
NEW AND Artemether is now registered
in over 30 endemic countries for
intramuscular injection in treat-
ment of severe malaria.
Artemether can be recom-
mended for treatment of schisto-
somiasis in areas where there is
no regular transmission of malar-
ia (e.g. north of the Sahara and
parts of the Middle East).
Lymphatic filariasis has been tar-
geted for elimination by 2020.
The key strategy is mass treat-
ment with a single,annual dose of
two-drug treatment:DEC plus al-
bendazole,or ivermectin plus 
albendazole.
Eflornithine is licensed for use
in sleeping sickness in the US, Eu-
rope, and 12 African countries.
Treatment of children in the ear-
ly chronic phase of Chagas dis-
ease with Benznidazole has be-
come common practice through-
out Latin America and guidelines
for clinical management have
been published.
Not only has TDR’s work led to
making these drugs available for
use in disease control, the work
has also resulted in TDR,over the
years,being able to refine and fur-
ther develop its strong and cus-
tomized managerial systems and
expand its global network of re-
searchers and developers capable
of addressing all the aspects of
R&D required to bring new drugs
from the earliest stages of dis-
covery through to registration.
TDR is a leading partnership
builder in this field.
Several new organizations are
now trying to replicate the mod-
els developed by TDR, particular-
ly in relation to building partner-
ships between the public and pri-
vate sectors.
What were the results?
izing small and large-scale field tri-
als in endemic countries following
standards and regulatory require-
ments compatible with registra-
tion in developed countries.Some
examples are:
Artemether, a derivative of
artemisinin,discovered and devel-
oped by Chinese scientists, for
malaria. In partnership with
Rhône-Poulenc Rorer,TDR spon-
sored, coordinated and provided
technical support for clinical trials
of artemether injection, and fur-
ther development of regulatory
data for its use in malaria.
Also, since the early 1990s,
evidence for prophylactic effects
of artemether on juvenile forms
of various species of schistosome
has been accumulating. Studies by
TDR and its partners have shown
that this drug could play a role in
breaking the transmission of schis-
tosomiasis in certain areas (where
it has already been very much re-
duced, but final eradication has
proved difficult, e.g. Saudi Arabia,
Morocco) and in control in cer-
tain areas (e.g. Egypt).
Ivermectin, was originally dis-
covered and developed by Merck
& Co. Inc. for use in animals, but
later, TDR provided substantial 
financial resources and technical
input for multi-country trials
against onchocerciasis. Ivermectin
is the major tool for treatment
and control of onchocerciasis.
More recently, TDR-sponsored
studies demonstrated that iver-
mectin used in combination with
Albendazole  in annual, single
doses, is effective for the control
of lymphatic filariasis in Africa.
TDR also supported studies that
demonstrated albendazole, toge-
her with diethylcarbamazine
(DEC),to be effective for the con-
trol of lymphatic filariasis in the
rest of the world. In the case of
albendazole,the industrial partner
is Smith-Kline Beecham (now
GlaxoSmithKline).
Eflornithine for African try-
panosomiasis was discovered
through basic science (it was orig-
inally developed by Hoechst Mar-
ion Roussel for treatment of can-
cer, but proved to be of little use
in the clinic). A TDR-supported
study of metabolic pathways in
trypanosomes led to the demon-
stration, in mice, that eflornithine
was effective against the enzyme
ornithine decarboxylase,a key en-
zyme in the multiplication of try-
panosomes. TDR supported the
work which led to registration of
eflornithine for use in sleeping
sickness in 1990. But, eflornithine
is expensive to produce so TDR
funded studies to find a new route
of synthesis, although these have
not yet borne fruit. Hoechst 
Marion Roussel (now Aventis)
granted a licence to produce
eflornithine to WHO, which is
working with MSF to identify new
manufacturers.
Benznidazole for Chagas dis-
ease.TDR/backed studies showed
that treatment of children in the
early chronic phase of Chagas dis-
ease with benznidazole, to stop
the disease evolving to irre-
versible cardiac lesions, is effec-
tive. (Benznidazole was previous-
ly only used in the acute phase of
Chagas disease).
 IMPROVED TOOLSWhen ivermectin
became available 
for the treatment of
onchocerciasis, and 
its potential for mass
treatment became
apparent, 85% of the
infected population
lived outside the range
of the Onchocerciasis
Control Programme in
West Africa (OCP). 
Why did TDR become involved?
In anticipation of the need for
rapid tools for identifying com-
munities endemic for onchocer-
ciasis, TDR had developed and
field tested methods for rapid
community diagnosis of on-
chocerciasis using palpation for
onchocercal nodules in a sample
of 50 adults. But TDR’s involve-
ment in research on rapid map-
ping followed from a specific re-
quest from the field.The key ac-
tors in onchocerciasis control
outside the OCP area at that time
were a group of international
non-governmental development
organizations (NGDOs) working
in blindness prevention.They had
established a coordinating group
with its secretariat in the WHO
Programme for the Prevention of
Blindness. The NGDOs wanted
to distribute ivermectin,but were
faced with the huge problem of
how to identify which communi-
ties to treat. The coordinating
group identified the need for a
means for rapid mapping and,
knowing TDR to be involved in
research on rapid assessment of
onchocerciasis,they turned to the
Programme for help.
Introduction
In OCP countries, control was based on tackling of the black-
fly vector through aerial spraying of insecticides over its
breeding sites in fast-flowing rivers. The advent of iver-
mectin presented a tool which could be used as the main
strategy for control in the remaining endemic areas not suit-
able for the OCP type of vector control. However, at first
there was a huge bottleneck because it was not known on
which areas and communities ivermectin treatment should
be focused. It was necessary to first determine the geo-
graphical distribution of the disease across countries or
regions, and identify the particular communities to treat,
before control programmes based on mass treatment could
begin. Thus, TDR helped develop a new tool to rapidly assess
the onchocerciasis situation – rapid epidemiological map-
ping of onchocerciasis (REMO).  
Using REMO, it is possible to assess quickly and cheaply
which communities are at high risk and where they are locat-
ed. Basically, REMO works by using geographical information,
particularly the presence of river basins, to identify commu-
nities likely to be at high-risk. A sample of these high risk
communities is then assessed rapidly for the prevalence of
onchocerciasis (by feeling for onchocercal-worm-containig
nodules in 50 adults per village). 
Rapid mapping for
onchocerciasis
Rapid mapping for 
onchocerciasis
NEW AND In developing REMO,TDR built on
the experiences of the On-
chocerciasis Control Programme
(OCP), whose detailed mapping
of onchocerciasis had led to un-
derstanding of the spatial distri-
bution of the disease, particularly
its relationship with river basins
and potential blackfly breeding
sites. TDR’s role in developing 
REMO was catalytic and very
proactive.It brought everyone to-
gether and got the process start-
ed. The need for REMO came
from the field,but development of
the method was driven from in-
side TDR.At that time,APOC had
not been established, although
subsequently TDR was to work
closely with this body. TDR also
worked closely within WHO with
HealthMap, to develop a geo-
graphical information system
(GIS) for analysis of the on-
chocerciasis data.
After developing REMO,TDR was
involved in further standardizing
the tool in conjunction with on-
chocerciasis control personnel.
The REMO manual was devel-
oped in several stages – an earli-
er edition was produced after the
initial trial in Cameroon, which
was later revised after a major
workshop in Nigeria, where first
application of the tool on a na-
tional scale was planned. Guide-
lines for analysis of REMO results
were subsequently developed 
to help onchocerciasis control
personnel interpret results from
REMO and use them to identify
priority areas for mass treatment.
TDR also carried out the first im-
plementation of REMO, its first
large-scale application, under
funding from the World Bank.
Several countries were complete-
ly mapped, including Nigeria,
Cameroon,Tanzania and Uganda.
Further implementation of 
REMO was taken over by APOC
in 1996,after establishment of this
Programme.
REMO has become a key tool 
in the control of onchocerciasis
and is used to provide basic in-
formation for rational planning 
of large-scale ivermectin treat-
ment in APOC countries. Com-
plete country maps, targeting the
areas for treatment, are available.
Integration of REMO results in a
GIS, overlapping the onchocerci-
asis map with a population map,
allows control programmes to
plan which communities to treat
and obtain better estimates of the
number to be treated and the
number infected, as well as a bet-
ter estimate of the burden of this
disease.
What were the results?
What was TDR’s role?
No REMO yet
No CDTI
CDTI unlikely (to refine)
Definite CDTI areas
CDTI likely (to refine)
Source: NOTF Nigeria, June 1998
Prepared by WHO/UNICEF HealthMap
for APOC
 IMPROVED TOOLSChagas disease, 
caused by the parasite
Trypanosoma cruzi,
exists only on the
American continent,
where it is endemic in
18 countries of Central
and South America.
In the whole of Latin
America in 1991, 
an estimated 
16-18 million people
were infected and
another 100 million
people were at risk 
of becoming infected.
Why did TDR become involved?
In 1977,TDR’s Scientific Working
Group on Chagas Disease identi-
fied several urgent needs: devel-
opment of new drugs; improved
methods to eliminate the parasite
from blood banks; better diag-
nostic testing; improved vector
control methods.There was em-
phasis on gaining better under-
standing of the geographical dis-
tribution, prevalence and clinical
varieties of Chagas disease and of
the distribution of its vectors.
By the early 1980s, it was recog-
nized that the only feasible means
of controlling Chagas disease was
through attacking the insect vec-
tor with insecticides. Housing im-
provements were seen as a com-
plementary viable option.
Introduction
Some 45 000 deaths occur annually from Chagas disease. The
disease is difficult to diagnose in its early stages, with most
infected people not exhibiting any significant clinical symp-
toms. However, some 45% of infected individuals move on to
the chronic stage, with irreversible damage to the cardiac,
digestive or neurological tissues, for which no treatment is
available. 
The disease usually afflicts people in rural areas and those
living in poor communities where houses are built from very
basic materials. Roofs are generally made of dried straw with
mud-plastered walls, providing a haven for the bloodsucking
triatomine bugs which transmit the disease to humans. In
recent years, the disease has also become a concern in urban
areas as well, when people migrate into the cities with the
parasite already in their bloodstream. Here, the disease is
transmitted via blood transfusions. 
Canisters, which release pyrethroid insecticidal fumes when
lit, have been developed and deployed in the fight against
Chagas disease since the 1980s. They are designed for use by
householders themselves. TDR also supported the develop-
ment of insecticidal paints, for use by spray teams. These
paints retain their insecticidal activity longer than tradi-
tional sprays. 
Vector control for
Chagas disease
Vector control for
Chagas disease
NEW AND IMPROVED Along with regional organizations
and bilateral agencies,TDR played
a crucial role in helping mobilize
resources at the global level to fi-
nance research on Chagas dis-
ease, and in international coordi-
nation and linking of researchers,
particularly those in endemic
countries,but also those in North
America and Europe. The result
was the establishment of a net-
work of national institutions,
working in collaboration with
government control programmes.
Scientists at the Centro de Inves-
tigaciones de Plagas e Insecticidas
(CIPEIN) began collaboration
with TDR in 1978. TDR funded
development of the canisters
from 1980, organized and part-
funded multicountry studies of
the new vector control tools (in-
secticidal paints and fumigant can-
isters), and helped establish a
standard protocol to evaluate the
studies. In most countries, the
paints were shown to reduce
rates of house infestation by a fac-
tor of 2-3 compared with con-
ventional spraying and to provide
an improved living environment.
The canisters,which are now pro-
duced and marketed by local in-
dustries, are employed optimally
to maintain insecticide levels in-
side houses.
Argentina, Bolivia, Brazil, Chile,
Paraguay and Uruguay began the
‘Initiative for the Elimination of
Chagas Disease by Southern
Cone Countries’ in 1991, using
fumigant canisters as one of the
tools to achieve this goal.
In the Southern Cone nations,
house infestation with triatomine
vectors fell by up to 90% be-
tween 1982 and 1994. Disease
transmission by vectors and
blood transfusion has now been
halted in Uruguay, Chile and
Brazil. Interruption of transmis-
sion in Argentina, Bolivia and
Paraguay is expected by 2003.
The fumigant canister is now al-
so being evaluated to fight an-
other disease vector,the mosqui-
to Aedes aegypti, which transmits
the virus causing Dengue.
What were 
the results?
What was TDR’s role?
PARTNERS
(fumigant canisters)  
• Ministry of Health
(Argentina)
• National Research Council
(Argentina)
• CHEMOTECHNICA, SA
(Argentina)
 INTERVENTION METHODS Trials have shown 
that the use of
insecticide- treated 
nets protect sleeping
children from being
bitten by mosquito 
vectors, resulting in
dramatic reductions 
in deaths among 
children under five.
Why did TDR 
get involved?
TDR’s played various role, acting
as a forum for ensuring that treat-
ed nets get taken more seriously
in the prevention of malaria, pro-
viding evidence of their efficacy.
TDR also helped to work out
strategies, along with WHO, for
product development and ways
of sustaining access to nets in
communities.
Another role was to stimulate the
private sector – the pesticide pro-
ducers – to develop formulations
and packaging adapted for home
treatment of nets. Dip-it-yourself
kits were designed, along with a
instructions for safe and effective
use of the kits,including where lit-
eracy is low.The instructions were
well tested in urban and rural
communities and illiteracy was
not found to be a problem, al-
though at the outset, the idea of
a dip-it-yourself kit for use in de-
veloping countries had been re-
garded with scepticism by most
people,including public health au-
thorities and chemical manufac-
turers.TDR also answered misgiv-
ings about the use of nets. One
concern was that use of the nets
would induce pyrethroid resist-
ance in the mosquito population.
But TDR studies indicated that,
even in areas where there is such
resistance,treated nets remain ef-
fective, and their use is unlikely to
induce resistance in malaria vec-
tors. Another concern was that
use of treated nets in hyper-
TDR became involved because of
its comparative advantage in see-
ing large-scale field trials through
to completion. This is due to its
organizational and financial staying
power made possible by its inter-
national backing and base. The
TDR trials were the largest trials
with nets ever carried out,involv-
ing altogether almost half a million
people,20 research institutes and
donors.They were carried out in
different epidemiological settings
with different malaria risks.
What was TDR’s role?
Introduction
Treating nets with a biodegradable pyrethroid insecticide has
added to their efficacy. The first TDR studies in 1990-91, in
the Gambia, showed a reduction of 63% in mortality from all
causes in children between the ages of one and five who had
slept under treated nets. Later trials in other countries
showed lesser, but still significant, reductions in mortality –
of 33% in the Kenyan trials and 17% in the Ghanaian trials.
In the Kenyan trials, the nets not only prevented deaths but
also led to a 40% reduction in hospital admissions for severe
malaria, indicating that their use could reduce the burden on
health services. The results of the trials suggested that some
500 000 African children might be saved each year from
malaria-related mortality if the nets were widely and proper-
ly used. As well as demonstrating the efficacy of treated
nets, TDR supported work to improve methods for their treat-
ment with insecticide. 
Insecticide treated nets Insecticide-treated nets
NEW AND IMPROVED endemic malaria areas might
merely shift the predominant age
of mortality to a higher age group
– that as children may not be in-
fected early in life, they will not
develop partial immunity to
malaria, and so will succumb to
the disease later in life. Findings
from TDR-supported studies in-
dicate that delaying infection is
not a problem.
Insecticide treated nets provide
one of the best malaria control
measures to date, and TDR oc-
cupied a catalytic role to bring it
all together.
The findings of the efficacy trials
emphasized that the contribution
of malaria to child mortality in
Africa had been underestimated
and that potentially large benefits
are to be gained from malaria pre-
ventive interventions.
The demonstration of efficacy of
the nets encouraged the private
sector to undertake product de-
velopment and bring new innova-
tions to the market (‘dip-it-your-
self’ kits; more durable nets; bed-
nets that don’t need re-dipping).
The first trials of treated bednets,
in the Gambia in 1990-91,
demonstrated their efficacy to
public health officials in the coun-
try,who became aware that treat-
ed nets are a very cost-effective
tool for fighting malaria, ranking
with some of the most efficient
health interventions available (e.g.
childhood immunizations). After
this,the Gambian government ini-
tiated a country-wide programme
for the implementation of net im-
pregnation in villages with primary
health care clinics.
People’s attitudes to nets are
changing, with more and more
households taking to them as
people recognize that using nets
is a way to save the lives of their
children.
Today, the use of treated nets is
an important part of the global
strategy proposed by WHO to
prevent people being infected by
vector mosquitos, and is one of
the main strategies adopted by
Roll Back Malaria.WHO’s Region-
al Office for Africa asked for a
‘phased and continuously moni-
tored implementation of treated
nets’. Overall, it is estimated that,
at the present time, less than 5%
of people at risk of malaria in
Africa, south of the Sahara, use
nets. However, the figures range
widely between different coun-
tries:
• In Nigeria, evidence shows that
less than 2% of the population
are aware of the effectiveness
of treated nets while less than
1% actually use them.
• In Tanzania, more than 70% of
households in Dar es Salaam
and more than 20% of house-
holds in many rural areas have
at least one net.
• In The Gambia (the only coun-
try where nets are used on a
wide scale),over 76% of the ru-
ral population have,and do use,
nets.
• In Vietnam, the number of peo-
ple protected by treated nets
increased from 300,000 in 1991
to almost 10.8 million in 1998,
although it is estimated that half
of the population of 75 million
is at risk of malaria.
Thus,TDR has helped prove the
principle of efficacy of treated
nets. But the challenge ahead is
not insignificant. With the goal for
African countries, under the RBM
banner, of 60% coverage of 
people at risk from malaria with
nets by 2005, there will be much
collaborative implementation re-
search, including integration of in-
secticide-treated net activities
with other health interventions
e.g.integrated management of the
sick child and mother-and-child
health.
What were the results?
PARTNERS
Funding partners:   
• United Nations Children’s
Fund (UNICEF) 
• United States Agency for
International Development
(USAID) 
• International Development
Research Centre (IDRC)
• Centers for Disease 
Control (CDC)
• Canadian International
Development Agency
(CIDA) 
• Wellcome Trust
• Save the Children Fund
• London School of Hygiene
and Tropical Medicine
• Italian Cooperation
Funded partners: 
Ministry of Health of: 
• Ghana  
• Tanzania 
• The Gambia 
• Kenya 
• Burkina Faso 
 INTERVENTION METHODS Early diagnosis and
prompt, effective treat-
ment of malaria is a
key strategy for malar-
ia control.1 The role
that home treatment
can play in this strate-
gy, especially for
Africa, became appar-
ent after better under-
standing of care seek-
ing behaviour was
reached. 
Why did TDR get involved?
TDR’s role has been to identify
possible problems that might im-
pact on the effectiveness of home
treatment, to urgently develop
and implement strategies to solve
these problems, and to provide
conclusive evidence of the effec-
tiveness and impact of home
treatment on the malaria burden.
In 1998, TDR constituted a task
force of experts who took re-
sponsibility for these activities and
committed themselves to work-
ing with multi-country,multi-disci-
TDR funded many of the studies
in treatment seeking behaviour2
that prompted the new strategy
for malaria control adopted by
the Roll Back Malaria initiative.
Through the work of the various
task forces in its Applied Field Re-
search area,TDR had established
a network of interested and able
teams in countries who could car-
ry out the research.The initial ex-
ploratory studies, formulated
mainly in the context of health
sector reforms, had identified po-
tential interventions e.g. training
of shopkeepers and vendors,unit-
dose packaging of antimalarials to
improve compliance, improving
Introduction
The majority of families treat their children at home using
antimalarials and/or antipyretics bought from drug vendors
and/or village shops as the first line of treatment. However,
families often buy insufficient amounts, there is very little
information provided with the treatment, and even when
they do receive the full course, compliance with treatment
recommendations is poor. The tendency is to stop treatment
as soon as the symptoms disappear, saving any remaining
tablets for future illness episodes. Despite these shortcom-
ings, at the Abuja Summit in April 2000, the heads of state
of most African countries, in the context of Roll Back Malaria
(RBM), committed themselves to ensuring that diagnosis 
and treatment of malaria is made available as peripherally as
possible, including home treatment, in an effort to make
appropriate treatment available and accessible to the poor-
est groups in the community.
What was TDR’s role?
community awareness for early
appropriate home treatment,
prompt referral of severely ill chil-
dren. These early, very localized
experiences formed the corner-
stone of the home management
package of interventions that have
been developed further and test-
ed through multi-country studies.
Unit-dose antimalarial packs Unit-dose antimalarial packs
NEW AND IMPROVED plinary teams to provide, within
five years, the answers to the fol-
lowing questions:Is it possible and
feasible to change the behaviour
and practices of mothers, house-
holds and communities in order
to increase the extent of early,ap-
propriate care for childhood un-
complicated fever episodes and
referral for severe illness in malar-
ia endemic countries? If strategies
which prove feasible and effective
in changing behaviour and prac-
tice were to be implemented on
a much wider scale, would they
have an impact on morbidity and
mortality? 
Country teams (Ghana, Nigeria,
Uganda, Burkina Faso) were se-
lected on a competitive basis. A
common framework was devel-
oped and proposals were devel-
oped along this framework.Fund-
ing and technical support was
provided to the teams.
To date, results have been ob-
tained from the Burkina Faso tri-
al.In Burkina Faso,researchers de-
signed a strategy for prompt and
adequate home treatment that in-
cluded: re-training of health staff
of the local health unit, informa-
tion/sensitization meetings and
training sessions for communities
from all study villages, and making
available pre-packaged antimalari-
al drugs containing a full course of
treatment through trained village 
volunteers. The drugs were pro-
vided in four different colour 
coded simple packages for differ-
ent age groups, following the
Burkina Faso treatment guidelines
(0-6 months, 7-11 months, 12-35
months and 36-69 months), each
containing a full course of treat-
ment and a label with pictoral in-
structions on how to administer
the drugs.A village volunteer sold
the drugs at a price previously
agreed with the local health man-
agement team, which was calcu-
lated to allow for full recovery of
the purchase costs and a 10% in-
centive margin for the volunteer.
Three hundred and seventy-five
villages participated in the study
and at least one volunteer was
trained in each village.Fifty-six per
cent of the children that were
treated by the village volunteers
complied with the treatment, in-
cluding the correct duration.
The rate of progression towards
complicated malaria  was lower in
children who were treated with
pre-packaged antimalarials (5.1%)
than in those not treated with
these drugs (11.0%). The overall
reduction of progression towards
severe disease among users of
pre-packaged treatment was
53.6%. In the four target age
groups, the progression rate to
severe malaria varied between
3% and 7.1% in children who re-
ceived pre-packaged antimalarials,
and between 8.1% and 18.2% in
the control group.
The feasibility, sustainability, cost
and effectiveness over time of the
strategy for home treatment of
malaria have not yet been
demonstrated on a larger scale.
This is a challenge for implemen-
tation research.
What were the results?
PARTNERS
• National institutions 
and ministries of health
• USAID (US Agency 
for International
Development)
• Roll Back Malaria
• Wellcome Trust
 INTERVENTION METHODS Community Directed
Treatment (ComDT) 
is a new approach 
to drug delivery in
which the community
is in charge of 
the planning and 
execution of treatment
of its own members. 
Why did TDR get involved?
Onchocerciasis is a major public
health problem, caused by infec-
tion with Onchocerca volvulus,
which results in visual impairment
and blindness, severe skin disease
and maddening itching. The dis-
ease has been controlled in the
West African savanna by the On-
chocerciasis Control Programme
in West Africa (OCP). But in the
other endemic areas,where more
than 80% of all infected people
live, OCP’s vector control strate-
gy was not feasible and these
countries were “left looking over
the fence”.This changed with the
emergence of ivermectin as an ef-
fective microfilaricide, its registra-
tion for the treatment of on-
chocerciasis in 1987, the devel-
opment and testing of a control
strategy based on mass iver-
mectin treatment, and the deci-
sion by Merck & Co. Inc. to do-
nate the drug (Mectizan®) free
of charge for onchocerciasis con-
trol for ‘as long as needed’.
In spite of this breakthrough,
large-scale ivermectin treatment
took off only slowly, as it was 
difficult for the health services 
to provide the required annual
round of mass treatment  for
onchocerciasis, a disease of the
poorest communities 'at the end
of the track'.As a result,it was ini-
tially only the OCP and a few in-
ternational NGOs who could en-
sure large-scale ivermectin treat-
ment, often using mobile teams.
To eliminate onchocerciasis as a
public health problem, annual
treatment needs to be sustained
over a very long time. Several at-
tempts were made, therefore, to
integrate ivermectin delivery in
primary health care, or to use
community-based approaches in
the many areas where health fa-
cilities were absent or not func-
tioning. As it was not at all clear
how effective these different ap-
proaches were, TDR was re-
quested to evaluate them with a
view to developing improved de-
livery methods that would be sus-
tainable.
Introduction
In ComDT, the community is empowered to take full respon-
sibility for the drug delivery process, to collectively decide
how and when to do the treatment, and to ensure adequate
implementation and follow-up. A TDR multi-country study
demonstrated, in 1995, the effectiveness of ComDT for iver-
mectin delivery. The method has subsequently been adopted
by all onchocerciasis endemic countries in Africa as the prin-
cipal strategy for drug delivery in onchocerciasis control.
Since then, ComDT has proven very effective in achieving the
treatment coverage required to eliminate onchocerciasis as a
public health problem, and in 2000, some 20 million people
received ivermectin treatment through ComDT. A recent
external evaluation of the African Programme for
Onchocerciasis Control (APOC), which covers 16 endemic
countries in Africa,  concluded  that ‘ComDT has been a time-
ly and innovative strategy ... and communities have been
deeply involved in their own health care on a massive scale
... ComDT is a strategy which could be used as a model in
developing other community-based programmes’. 
Community-Directed Treatment Community-Directed Treatment
NEW AND IMPROVED POLICIES, PREVENTION In 1994, TDR launched a multi-
country study involving eight mul-
ti-disciplinary research teams
from five African countries to
evaluate and further develop
methods for community-based
ivermectin delivery. Early in the
study, the researchers discovered
that there was little active com-
munity involvement in the ‘com-
munity-based’ approaches, and
that communities had virtually no
influence on how treatment was
planned and executed. But social
scientists on the teams noted that
these same communities routine-
ly organize much more complex
traditional community activities
very effectively. This led to the
idea of community-directed treat-
ment in which the community 
itself would be in charge of the
design and implementation of
ivermectin treatment. This con-
cept was tested in the second
phase of the study through a
large randomized comparison in
272 communities of true 'com-
munity-directed' treatment ver-
sus 'community-based' treatment
(as designed for communities by
control programmes.) 
It was clearly demonstrated that
ComDT is feasible and effective.
Communities could effectively
plan and implement ivermectin
treatment, and they achieved
higher treatment coverage if they
were empowered to design and
implement treatment their own
way. It was concluded that
ComDT is likely to be sustainable
because of the commitment
demonstrated by community
leaders and community distribu-
tors, the high degree of involve-
ment of communities, and their
ability to recognize problems with
their distribution methods and ef-
fectively modify them.On the ba-
sis of TDR’s work, ComDT was
adopted by OCP as its ivermectin
delivery strategy and it became
the principal control strategy for
the APOC programme in 1996.
The main objective of APOC is
now “to establish effective and
self-sustainable community-di-
rected ivermectin treatment
throughout the remaining en-
demic areas in Africa.”
The large-scale implementation
of ComDT produced important
new challenges and APOC re-
quested TDR to help strengthen
the evidence base for ComDT
and undertake research on criti-
cal implementation problems.
These included issues relating 
to the integration of ComDT in
the health services and the sus-
tainability of ComDT after cessa-
tion of APOC support.Follow-up
studies showed that, although
health workers initially had a neg-
ative attitude to active communi-
ty involvement in drug delivery,
their attitude became much more
positive after experience with
ComDT. Poor communication
and interaction between commu-
nity members and health workers
was also common but research
showed that local stakeholders
meetings of community repre-
sentatives and health workers
could significantly improve this
and further enhance a positive at-
titude of health workers. The 
current research focus is on the
ability of countries and health sys-
tems to support ComDT after
APOC/OCP and on the use of
ComDT for multi-disease inter-
ventions. The effectiveness of
ComDT for the treatment of lym-
phatic filariasis has already been
demonstrated in a multi-centre
study in Africa. ComDT achieved
coverage of over 80%, as com-
pared to 45% by the health 
services. In this study, the issue of
integration was addressed from
the start and ComDT was intro-
duced to the communities by 
the health services themselves.
ComDT is now also recom-
mended for mass treatment for
lymphatic filariasis elimination in
Africa.
What were the results?
What was TDR’s role?
 AND CONTROL STRATEGIESVery few new drugs
for tropical diseases
reach the market 
and, even if they 
do, there are huge
inequities in access 
to drugs between rich
and poor countries.
Why did TDR 
get involved?
TDR has helped bring a number
of drugs into disease control use.
Below are some examples:
To expand the use of
artemether for disease control
use for malaria,TDR negotiated a
preferential price for the public
sector with the manufacturer,
Rhone-Poulenc Rorer Doma. A
collaborative agreement was
made with this company whereby
data from TDR-funded non-clini-
cal and clinical studies were ex-
changed for the preferential price.
The necessary safety and efficacy
data were completed by the
manufacturer.
To bring ivermectin into disease
control use for onchocerciasis,
TDR negotiated with the interna-
tional pharmaceutical manufactur-
er,Merck & Co.Inc.,for the supply
of ivermectin, and with the On-
chocerciasis Control Programme
(OCP) for provision of advice on
how to distribute and monitor the
drug in Africa. Merck & Co. Inc.
donated ivermectin for onchocer-
ciasis for ‘as long as necessary’. It
provided 92 million tablets in
1999 alone through 29 countries.
To bring albendazole into dis-
ease control use for lymphatic fi-
lariasis,TDR helped negotiate with
the manufacturer, Smith Kline
Beecham (now GlaxoSmithKline),
who pledged, in 1998, to donate
albendazole to WHO for ‘use by
governments and other collabo-
rating organizations until lymphat-
ic filariasis is eliminated from the
world as a public health problem’.
Because,even though a new drug
may be available, i.e. has reached
the market, it may not be acces-
sible to those who need it, for a
variety of reasons. For instance, it
may be expensive to produce
and hence to buy, so poor and
marginalized populations who
need it cannot afford to buy it.
TDR, from its base within the
United Nations system, its long
history of partnership with in-
dustry, the donor and developing
country research and control
communities, is in a strong posi-
tion to act as a broker between
the different stakeholders. The
aim is to make drugs accessible
to those who have the needs but
not the means to reach the drugs
via the usual market mechanisms.
What was TDR’s role?
Introduction
The international pharmaceutical industry, with few excep-
tions, has shown little interest in drugs for tropical diseases
due to market and government failures and enormous income
differences. Lack of money, lack of drugs, poor quality and
counterfeit drugs, prohibitive cost, incorrect use due to lack
of training or lack of information, all lead to inaccessibility
for the poor. There is a need to develop field-based drug
research to determine optimum utilization and remotivate
research and development for new drugs for the developing
world, as TDR is attempting to do through forming partner-
ships between the public and private sectors and between
the developed and developing worlds. This snippet high-
lights some examples of how TDR has helped bring new drugs
into disease control use. 
Getting drugs into
wide control use
Getting drugs into 
wide control use
NEW AND IMPROVED POLICIES, PREVENTION In 1999, the use of artemether
as intramuscular injection for
treatment of severe malaria was
expanded to more than 30 en-
demic countries and the drug was
included (restricted use) in the
WHO Model List of Essential
Drugs.
Mass treatment of lymphatic 
filariasis consists of a single dose
of two-drug treatment – of 
DEC  plus  albendazole,o r
ivermectin plus albendazole.
This is the basis of the strategy for
elimination of lymphatic filariasis
by 2020. Since the programme
was initiated (2000), SmithKline
Beecham has provided 34 million
tablets of albendazole through
WHO. WHO/TDR facilitated 
the procurement of 115 million
tablets of DEC, and Merck and
Co. Inc. provided ivermectin for
the Ghanaian, Nigerian and Tan-
zanian lymphatic filariasis pro-
grammes.
The search for potential manu-
facturers of eflornithine had
led, by January 2001, to the iden-
tification of eight companies.
One of these had produced a
sample which was being chemi-
cally analysed, in January 2001, to
see if it met purity specifications.
By February 2001, firm plans for
production and supply of eflor-
nithine were in sight.
What were the results?
To bring eflornithine into dis-
ease control use for the gambi-
ense form of African trypanoso-
miasis,TDR was involved in nego-
tiations with the private and non-
governmental sectors.This drug is
very expensive to produce, but is
very much needed, particularly
where resistance to arsenicals has
become a problem. Eflornithine is
now no longer manufactured, but
the manufacturer, Hoechst Mari-
on Roussel Inc., has granted
WHO reference right to produce
eflornithine. This will allow tech-
nology for production of the drug
to be transferred to a third party,
also in the private sector,who will
manufacture eflornithine.
Médecins sans Frontières (MSF),a
non-governmental organization
that has made great efforts to
contain Sleeping Sickness, helped
to search for the third party who
would manufacture eflornithine.
Together, TDR and MSF ap-
proached donors who, it was
hoped, would provide funds to
guarantee production of eflor-
nithine, initially for five years.
 AND CONTROL STRATEGIESTDR is a global 
leader in fostering
partnerships that 
generate new knowl-
edge about tropical
diseases and in bring-
ing researchers
from developing
disease endemic
countries into 
the mainstream 
of research to find
solutions to the pub-
lic health problems
related to TDR’s 
target diseases.
Why did TDR 
get involved?
TDR has a role as catalyst, facili-
tating the R&D agenda through
setting priorities, funding projects,
and bringing together partners
who have the comparative ad-
vantages required to make end-
products become realities. TDR
has unique operational capabili-
ties which allow it to bring to-
gether the world’s leading re-
searchers and product develop-
ers, from both public and private
sectors and both developing and
developed countries.These capa-
bilities allow TDR to fund and
manage, in an efficient, account-
able, and transparent way, a large
number of research and product
development projects as well as
the knowledge and capacity they
generate.
During the past decade,TDR en-
gaged with 2631 new partners in
124 different countries. These
partners were engaged directly to
undertake research and develop-
ment, build research capacity in
developing countries, develop re-
search tools, or to provide sup-
port and technical advice.
TDR is a knowledge management
and network organization, which
manages the generation and ap-
plication of knowledge through
linking and brokering the stake-
holders and processes needed for
fostering and applying new knowl-
edge to effectively combat tropi-
cal diseases.TDR also has the goal
of strengthening capacity in dis-
ease endemic countries to un-
dertake the research required for
developing and implementing
new and improved disease con-
trol approaches. TDR believes
that knowledge is a crucial ele-
ment in health improvement, and
that the attainment of self-re-
liance in research and develop-
ment in disease endemic coun-
tries is key to sustainability.
What was TDR’s role?
Introduction
Today there is an imbalance in generation of knowledge and
research funding: only 10% of global research funding is
spent on diseases or conditions that account for 90% of the
global disease burden (a situation known as
the ‘10/90 gap’). TDR is about closing this
gap. In addition to looking at the physical
products, e.g. drugs, tools, guidelines, it is
in the scientific literature that the results
of TDR efforts in capacity building and
promotion of research in disease endem-
ic countries can be found. 
Partnerships in science Partnerships in science
PARTNERSHIPS AND A Wellcome Trust study on in-
ternational funding for malaria re-
search in 1998 concluded that,of
six major funding bodies and rel-
ative to the financial investment
of each, TDR had the highest
number of acknowledgements
per unit of investment, and over-
all the most funding acknowl-
edgements;and that,according to
citations to published papers,
TDR’s performance was in line
with other top funding bodies. In
another Wellcome Trust study on
malaria research capacity in
Africa,TDR came out top of the
list for all indicators used, includ-
ing source of funding for African
malaria research laboratories,and
master’s degree and PhD training
for African researchers.
A Harvard University analysis 
revealed TDR to be the leading
funding source for research on
African trypanosomiasis, leish-
maniasis, leprosy, malaria and 
onchocerciasis, ranking second
for Chagas disease, filariasis and
schistosomiasis. More than 83%
of TDR funded papers were cit-
ed at least once, and frequently-
cited papers were not confined
to authors from industrialized
countries – of the 24 most high-
ly cited papers in all subject ar-
eas, four were authored by peo-
ple from developing countries.
This is a significant percentage –
some 16% – when considered in
the light of the well-known bias
of English-speaking industrialized
country journals towards authors
from industrialized countries
(overall, less than 0.01% of arti-
cles indexed in MedLine originat-
ed in developing countries).
What were 
the results?
Frequency of funding acknowledgements 
citation in randomly selected papers 
(Michaud 1998)
TDR   Other major Others 
Disease (% of total  funders  (% of total
papers) (top three) papers)
African 
trypanosomiasis 51 NIH  (USA) 15
European Commission 15
Wellcome Trust 9
Chagas disease 30 CONICET (Venezuela) 39
FINEP (Brazil) 28
NIH (USA) 15
Filariasis 27 ICMR (India) 38
CNPq (Brazil) 8
Edna McConnell Clark 
Foundation 5
Leishmaniasis 33 CNPq (Brazil) 32
NIH (USA) 6
Leprosy 25 LEPRA (Malawi) 21
NORAD (Norway) 14
SIDA (Sweden) 8
Malaria 30 NIH (USA) 17
Wellcome Trust 12
USAID (USA) 11
Onchocerciasis 39 NIH (USA) 28
European Commission 24
Wellcome Trust 10
Schistosomiasis 22 European Commission 23
Edna McConnell Clark 
Foundation 18
CNPq (Brazil) 9
Note:
CNPq, Conselho Nacional de Desenvolvimento Científico e Technológico;
CONICET, Consejo Nacional de Investigaciones Científicas y Technológicas;
FINEP, Financiadora de Estudos e Projetos; ICMR, Indian Council of 
Medical Research; LEPRA, Leprosy Relief Association Control Project; NIH,
National Institutes of Health; NORAD, Norwegian Agency for International
Development; SIDA, Swedish International Development Cooperation
Agency; USAID, United States Agency for International Development. 
 CAPACITY BUILDINGWhy did TDR get involved?
Closing the global gap in research
and product development be-
tween the rich and the poor, and
increased involvement of re-
searchers from developing coun-
tries, are derived from the core
values on which TDR is founded.
One of the two goals of the Pro-
gramme is to increase self-re-
liance in endemic countries for
identifying needs and developing
solutions to the public health
problems caused by neglected in-
fectious diseases that affect them.
Building research capacity has
Introduction
Studies have shown that up to 30% of African scientists are
lost to the brain drain. The brain drain not only has severe
implications for the ability to build and maintain a critical
mass of tacit knowledge and skills in these countries, it also
means less research being done that is relevant to the prob-
lems of the least developed countries. A major contributing
factor is the limited opportunities, after training, to conduct
meaningful research as national research funding is extreme-
ly scarce and international funding is often biased towards
already established institutions. TDR’s highly customized,
integrated, and seamless approach to capacity building and
research funding represents one of the few mechanisms for
researchers from least developed countries to be involved in,
and for building a sustained basis for, research of local and
international relevance. 
Partnerships at both the individual and institutional level,
networking and promoting equal opportunities, gender and
geographical balance among DEC researchers, constitute the
core of TDR’s approach to building research capacity. This
approach has proven highly effective in many countries
where TDR continues to collaborate with scientists whose
research groups received early support from TDR. Many of
these groups now participate in the global research agenda,
from basic biological and social science to research into how
new policies and strategies are best introduced into coun-
tries’ health systems. Many developing countries’ research
and training centres are now also engaged in helping to
build research capacity in other developing countries.
‘Tacit’ knowledge and
skills are different from
‘codified’ knowledge as
found e.g. in published
literature. Tacit knowl-
edge and skills are
embodied in people 
and are learnt through
actual training, e.g. in
laboratories and 
universities. Disease
endemic countries
(DECs), in particular
the least developed, 
are losing their tacit
knowledge as highly-
skilled researchers 
are finding employment
elsewhere, often result-
ing in shifting research
away from advance-
ment of knowledge to
creation of wealth. 
Building research capacity in 
least developed countries
Building research capacity in 
least developed countries
PARTNERSHIPS AND TDR’s research capability
strengthening activities have re-
flected the changing capacities
and infrastructures in DECs. In
TDR’s formative years, support
concentrated on large-scale insti-
tution strengthening, often involv-
ing the provision of crucial equip-
ment and support for multi-dis-
ease or cross-disciplinary re-
search projects.With the evolving
scientific capacities and infrastruc-
tures in many DECs in the late
1980s, the emphasis shifted to a
balance of institution and individ-
ual support where priority was
given to human resource devel-
opment. Research training grants
are awarded on a highly compet-
itive basis to applicants with fixed
employment in a relevant re-
search or control position, there-
by facilitating a direct impact on
research and control.
With its new strategy,TDR has es-
tablished two main tracks in its
approach to capacity building.
One track is driven by the R&D
output, i.e. leading research insti-
tutions,from least as well as more
advanced developing countries,
are invited to compete for par-
ticipation in R&D work con-
tributing directly to TDR’s R&D
agenda and to build capacities to
become more internationally
competitive.The other track is re-
served strictly for researchers
from least developed countries
and aims more broadly to lay sol-
id foundations for building future
sustainable research capacities in
these countries.
What was the impact?
What was TDR’s role?
TDR has supported over 1000
trainees from 416 research
groups and institutions drawn
from 76 developing countries.
TDR is often considered unique
among funding agencies in that
over 95% of its trainees return to
their countries to continue work-
ing in their areas of specialty.TDR
encourages applications from
women, and over one third of
funded individuals have been
women.The majority of TDR PhD
graduates (60%) have published
more in the post-grant period
than the pre-grant period. TDR
graduates have higher success
rates than non-TDR graduates in
applying for re-entry grants (57%
versus 30%), and TDR graduates
have similarly higher success rates
in receiving TDR R&D funding
than non-TDR graduates (the
TDR steering committee funding
averages being 58% and 30% 
respectively).
TDR has played a significant role
in boosting overall research capa-
bilities in developing nations. Be-
tween 1970 and 1985, the num-
ber of skilled people engaged in
research in Africa rose by a factor
of 10 and funds for R&D in-
creased 7-fold over the same pe-
riod.In the past decade,there has
been an extraordinary growth of
scientific knowledge and tech-
niques with application to tropical
disease research. Much of this
knowledge has come from re-
search in developing countries.
More importantly,there is a grow-
ing ability of these countries to
make use of this knowledge.From
TDR’s viewpoint, the result has
been a new cadre of public health
and scientific research leaders and
specialists.Past TDR grantees now
provide opportunities to train
young scientists to develop re-
search teams, and to promote
partnerships.Former TDR trainees
and supported institutions now
play pivotal roles in research as
well as in control and health pol-
icy making, nationally, regionally,
and internationally.
been a major component of 
TDR since its inception.
Over the years, TDR has estab-
lished managerial systems and ca-
pacity strengthening approaches
which can handle large numbers
of trainees and ensure appropri-
ate re-entries and maintenance of
a research base in home coun-
tries. The dual role of TDR, as a
funding agency for capacity build-
ing as well as for actual conduct
of research and product develop-
ment,forms the basis for its com-
parative advantage as one of the
world’s lead organizations in re-
search capacity building.
 CAPACITY BUILDINGTDR’s technology
transfer initiatives 
aim to help advanced
developing countries
improve their own
research and 
development (R&D)
capacities. 
Technology transfer Technology transfer
A profound need for new prod-
ucts for tropical diseases has long
been recognized.TDR became in-
volved because the pace of emer-
gence of drug resistance and con-
sequent drug obsolescence, and
the rate at which therapeutic
agents were losing their effective-
ness, was not being countered by
current research.This is partly due
to the lack of activity by agencies,
institutions and commercial en-
terprises in both the public and
private sectors in the West,
founded on the poor economic
conditions in tropical regions and
the prospective poor return on
investments.There was – and re-
mains – a need for transfer of
technology to advance and pro-
mote research and development
capabilities for tropical diseases
through collaborative activities.
Furthermore,the cost of effective
medicines is often out of reach for
healthcare programmes in many
tropical regions,creating the need
for both discovery and develop-
ment of new products for tropi-
cal diseases and mechanisms to
help those most in need get ac-
cess to whatever tools become
available. Technology transfer to
disease endemic countries might,
for example, result in production
of cheaper, and hence more ac-
cessible, medicines.
Thailand is highly suited as a loca-
tion because it boasts a corps of
well-trained scientists, resources
to support research, more than
sufficient patients infected by or
open to infection with target dis-
eases, and a broad range of natu-
ral products which are sources of
potential new drugs and active
compounds.
Introduction
An excellent example of the initiatives in which technology
has been transferred through TDR activities is the Thailand
Tropical Diseases Research Programme (T-2). This pro-
gramme, established in 1997, comprises an organization
which promotes research into new product (drugs, vaccines,
diagnostics) development and screening. TDR partners in
this venture are the Thailand Research Fund, and the
National Science and Technology Development
Agency/National Center for Genetic Engineering and
Biotechnology of Thailand (NSTDA/BIOTEC).
Why did TDR become involved?
PARTNERSHIPS AND As a co-founder of T-2, and with
its expertise,experience and rep-
utation, TDR plays an important
role in overall programme man-
agement. TDR orchestrates re-
search assistance to T-2 through
its connections with universities
and pharmaceutical companies,
providing the important interna-
tional context to facilitate linkages
and promote 2-way information
flow between Thai and foreign
expertise, and plays a role in the
evaluation of research perform-
ance and results and making rec-
ommendations for further action.
Within the T-2 consortium
arrangements,TDR is the instru-
mental factor in building and con-
solidating networks of re-
searchers and entrepreneurs.
From this base,TDR has catalysed
research on its target diseases (T-
2, amongst its other diseases, car-
ries out research on malaria,
dengue, filariasis and tuberculo-
sis).Of special relevance,TDR has
sponsored and conducted work-
shops on good clinical practice
(GCP) and good laboratory prac-
tice (GLP).The implementation of
these practices will ensure that
the data produced from drug and
vaccine development studies are
of high quality and reliable, and
therefore internationally valid.
While TDR’s role is in providing
the important international con-
text to facilitate linkages, the role
of the Thai partners is in provid-
ing the important Thailand-based
research context under which 
T-2 operates, as well as in coor-
dination to convene, arrange and
cover the costs of all meetings of
the international advisory and
steering boards.
Within the first two years (1998-
99):
• technology transfer had oc-
curred through exchange of
Thai and foreign investigators
and training of investigators 
in specialized fields (e.g. me-
dicinal chemistry, screening of
biological activity) in Thailand
and abroad.
• and following the first
TDR/GLP workshop in Thai-
land, subsequent workshops
had been conducted in-coun-
try by the original trainees.
• a new antimalarial was under
development – a combination
of an artemisinin derivative
plus mefloquine.
• in a high-throughput screening
system, 6424 samples of Thai
natural products and synthetic
compounds had been
screened using a newly-devel-
oped and simplified method,
with 985 returning positive an-
timalarial indicators. Some are
being further evaluated.
• researcher had developed 
a PCR method to detect
Wuchereria bancrofti in mos-
quitos – which could be used 
as a tool to monitor and eval-
uate the filariasis control pro-
gramme in Thailand.
• two special tuberculosis labo-
ratories had been established.
In one, more than 2200 sam-
ples of pure compounds and
natural products had been
screened for anti-TB activity. In
the other, research is ongoing
on characterization of strains 
of  Mycobacterium tuberculosis
in Thailand (1567 strains col-
lected in first 2 years).
What were the results?
What was TDR’s role?
 CAPACITY BUILDINGChina is now well on
the way to producing
a sizeable body of
high-class research 
on schistosomiasis.
Research institutions
have been strength-
ened, experienced
scientists established,
and a much improved
network for schistoso-
miasis control in
China developed. 
Why did TDR become involved?
Especially important was TDR’s
role in advising on, assessing and
providing systems for managing
research proposals and projects.
By sponsoring expert advisors to
the JRMC, 245 projects were 
selected for support out of more
than 800 submitted for consider-
ation, 6 workshops were organ-
ized,and 23 young scientists were
trained abroad. In using its oper-
ational capability of acting as a
catalyst, TDR provided sustained
input to the mobilizing and galva-
nizing of scientists working in 
academic institutions and staff di-
rectly occupied in control activi-
ties.
TDR became involved because of
its interest in promoting research,
research capacity building and
linking closely with control activi-
ties. JRMC was seeking solutions
through research and the speed-
ing up of implementation of new
findings in the field, a focus of
TDR. It functioned as the re-
search arm of the consolidated
effort to eliminate schistosomia-
sis as a public health problem in
China, organizing nationwide co-
operative research on common
problems for policy, management
and methods in schistosomiasis
control. Thus the JRMC goals
were in keeping with the TDR
goals of reducing morbidity
caused by neglected tropical dis-
eases, and increasing the self-
reliance of endemic countries in
research. The end products of
JRMC, like those of TDR, are so-
lutions to public health problems.
What was 
TDR’s role?
Introduction
Research was a fundamental part of the overall effort for
control of schistosomiasis in China, supported by a World
bank loan. A Joint Research Management Committee (JRMC)
was set up to administer the research programme, to which
TDR contributed by supporting the participation of four advi-
sors – two staff members and two outside experts. The JRMC
strategy was to ensure cost-effectiveness of the chemother-
apy programme, improve health education, encourage devel-
opment and implementation of serologic diagnostic tech-
niques, develop new approaches to schistosomiasis control,
and help raise the quality of management. In 1995, activi-
ties became concentrated on surveillance and treatment,
with a strong focus on diagnostic techniques, geographical
information systems (GIS), prevention of schistosomiasis by
application of new drugs (artemether), and cost-effective
control management in different types of endemic areas. 
Schistosomiasis control 
capacity in China
Schistosomiasis control
capacity in China
PARTNERSHIPS AND In all, during the seven years, 278
theses were published, 25 proj-
ects were awarded prizes, and 
7 projects generated patents.
The development of novel ap-
proaches to chemotherapy
turned out to be the field where
the most important discoveries
were made. Several new control
tools were produced which may
improve future control approach-
es. Some notable achievements
were:
• use of artemisinin derivatives in
prevention of schistosomiasis –
a novel application of arte-
misinin derivatives (otherwise
used for malaria) which is
probably the most important
discovery in the field of schis-
tosomiasis in recent years.
• cost-benefit analyses of various
strategies, e.g. of targeted
chemotherapy compared to
mass chemotherapy in heavily
endemic areas – targeted
chemotherapy was found to be
cost-effective in highly endem-
ic areas.
• advances in immunodiagnosis,
including the establishment of
a national reference centre
with provincial serum bank.
• implementation of a new tech-
nique to control snails spread-
ing with the river irrigation 
systems (a patent granted on
this technique).
• improved methods for the sur-
veillance of cercariae-infected
water – a new and better
method was developed which
is now taught in training cours-
es and used in endemic areas
of several provinces.
• application and evaluation of
school-based health education
emphasizing the risk for schis-
tosomiasis.
• techniques for rapid evaluation
of schistosomiasis in lake and
marshland regions, and the na-
tional schistosomiasis surveys
for evaluation of the control
project after the first five years.
• development, application and
evaluation of a rapid diagnostic
kit for the detection of Schisto-
somiasis japonicum circulating
antigen.
• the development of a new mol-
luscicide (awarded a patent).
The overall impact on endemici-
ty and, particularly, on the intensi-
ty of disease due to schistosomi-
asis during the seven years was
favourable. In one province, schis-
tosomiasis was declared eradicat-
ed and, in others, the number of
villages classified as endemic was
reduced by 20-50%.
As schistosomiasis is now ap-
proaching elimination as a public
health problem in may areas in
China,the researchers who were
trained and given opportunities
under this programme are now
moving on to apply their skills 
and knowledge to solve other
public health problems.
What were the results?
 CAPACITY BUILDINGAccess to, and
exchange of, informa-
tion has increasingly
become a determinant
for progress in science. 
Why did TDR become involved?
Using its full range of in-house sci-
entific, communications, and in-
formation technology expertise,
and working closely with special-
ists in its co-sponsoring agencies,
i.e.UNDP,World Bank and WHO,
TDR has remained at the fore-
front of electronic publishing with
regard to development and pro-
duction of material on all aspects
of its target diseases and related
research activities. TDR takes
complex, highly specific and often
jargon-filled scientific research da-
ta, and reworks and repackages it
in a format easily digestible and
understandable for dissemination
via the Internet. In addition,TDR
As a network and knowledge
management organization, com-
munication is an essential com-
ponent of TDR's work. Dissemi-
nating and providing access to sci-
entific and technical information
on target diseases, new control
tools and methods,best practices,
and research needs and results, is
an important part of TDR's ob-
jectives. Provision of information
on TDR's progress, transparency
in operations, and advocacy to
raise awareness and draw atten-
tion to, and support for, TDR's
work, are also of critical impor-
tance.
Although the so-called 'digital di-
vide' still puts researchers from
developing countries at a disad-
vantage as compared to their col-
leagues from industrialized na-
tions,TDR's production of web-
site (and other) CD-ROMs, to-
gether with support of initiatives
to improve Internet connectivity,
aim to narrow the information
gap for TDR scientists.
With respect to access to,and ex-
change of,information relevant to
research in tropical diseases,TDR
aims to become a world-leading
hub.
What was TDR’s role?
Since the invention of the World Wide Web, a revolution in
the way information and data are communicated and shared
has taken place. In the early 1990s, TDR was among the first
in the area of health research to exploit the potential of the
Internet and World Wide Web. In 1993, TDR established an
email listserv, the tdr-scientists list, and a couple of years
later, TDR published its first web page. Today, with some 1000
pages and 350 links to external websites, the TDR website
forms the backbone of TDR's electronic communications activ-
ities, which also include digital photography, CD-ROMs, video
and television. Continually evolving using the latest and most
appropriate technologies, the website represents a major
vehicle through which TDR reaches its target audiences
throughout the world, and through which researchers can
reach each other.
Introduction
Internet communications Internet communications
DISSEMINATION OF INFORMATION, GUIDE TDR website
Pageviews per month by user category (in 2000)
0
5000
10000
15000
20000
25000
30000
April May June July August Sept. October Nov Dec
Industrialized countries
Unresolved/Unknow*
. net*
Developing countries
Non-profit*
. int*
* country of origin unknow
The TDR website and listserv
have become important media
through which TDR disseminates
and exchanges information.Serv-
ing initially as an outlet for pro-
viding information on grants,
research priorities and deadlines
for proposals (including online
application forms), the website
underwent a major redesign in
June 1999 to also include:
• General information on TDR:
strategy, organization, gover-
nance,resources and outcomes
• Interactive versions of TDR's
Programme Report and re-
search highlights
• A complete set of TDR's Final
Report Series presenting lead-
ing examples of TDR-support-
ed projects
• Multimedia resources,including
videos, and searchable access
to the TDR image library – 
a unique catalogue of over 
12 000 images
• A complete listing of TDR pub-
lications and reports available
to download
• Latest news from TDR
• Web-based discussion forums
and trainee profiles to facilitate
contact and information ex-
change between researchers
(in the pipeline).
Key information is simultaneously
posted on both the website and
listserv, and coordinated use of
other electronic and traditional
publishing methods ensures that
TDR meets the needs of those
with zero,poor or unreliable con-
nectivity.
In January 2001, the TDR website
received approximately 70000
pageviews – almost twice as 
many as the previous year.
Over a 5 month period in 1999,
250 feedback emails were re-
ceived via the site from 60 differ-
ent countries.
With only 50 subscribers at the
outset, the tdr-scientists list now
has close to 2000 participants,
35% of whom are developing
country scientists. At least 8% of
visits to the TDR website originate
from developing countries. Many
of those visits from unresolved or
unidentified locations (61% of the
total) may also be from develop-
ing countries. New content is
posted to the website and the list-
serv on an almost daily basis.
What are the results so far? maintains a web-based network-
ing area on its website, with links
to over 350 related external web-
sites and discussion groups – in-
formation reported by sub-
scribers to the tdr-scientists email
list and thus of interest to the
wider tropical disease research
community.These pages have re-
ceived several awards for a 'clean
bill of health', and are among the
most frequently visited pages on
the TDR website.
Since 1994,TDR's support of par-
asite genome projects have
helped to establish databases and
blast servers, which are all now
accessible via the Internet (see
Parasite Genome snippet).
TDR website:
www.who.int/tdr
tdr-scientists list: 
To subscribe, e-mail to
majordomo@who.int 
and type the following in
the body of the message:   
subscribe tdr-scientists
 LINES, INSTRUMENTS AND ADVICE‘Good practices’ in 
preclinical and 
clinical trials of new
drugs and vaccines
have been used as a 
standard by drug 
regulatory authorities
in industrialized
countries for over 
20 years. 
Why did TDR become involved?
TDR became more involved in
drug and vaccine development
for tropical diseases as the phar-
maceutical industry became less
interested in this therapeutic area
and the need for disease endem-
ic countries to play a greater role
in drug and vaccine development
became evident. When TDR be-
gan to promote good practices
(1999),the facilities and expertise
necessary for implementation of
these practices were virtually
non-existent in disease endemic
countries. So TDR began to sup-
port transfer of good practices 
to disease endemic countries
through training workshops and
production of guidelines.
TDR produced ethics guidelines
in an attempt to begin the process
of strengthening ethical review in
biomedical research in disease en-
demic countries. Although inter-
national ethics guidelines and
standards for carrying out bio-
medical research do exist, they
are at a theoretical level,and there
was a need for guidelines that
were practical (operational). The
TDR guidelines will enable local
ethics committees to develop
their own specific review proce-
dures needed to ensure the pa-
tient is not exploited. Implement-
ing the standard informed con-
sent procedures – whereby each
patient receives an explanation of
what the trial is about and gives
Introduction
Use of standard practices ensures that drug/vaccine devel-
opment studies are up to acceptable standards. If disease
endemic countries are to play a greater role in drug and vac-
cine development, there is a need to ensure that good prac-
tices are followed in order that data produced are high qual-
ity, reproducible and acceptable to drug registration author-
ities everywhere. A developing country will then be able to
market the products it has developed in the rest of the
world.
All data obtained from preclinical and clinical trials are ulti-
mately used by regulators to authorize marketing of the end
product. Preclinical development of a compound, during
which its safety is evaluated and the data obtained used to
make decisions regarding first use of the product in human,
involves examining the compounds in vitro and in animal
models. If results from preclinical safety studies are satis-
factory, the compound enters the clinical stages of develop-
ment, in which it is examined in human for safety and effi-
cacy.
Apart from complying with international standards of prac-
tice, all biomedical research has to comply with established
international guidelines concerning ethical and scientific
review of the research, including providing patients with full
information so that their consent to participate is informed.
Guidelines to good practices Guidelines to good practices
DISSEMINATION OF INFORMATION, GUIDE TDR’s role was to convene meet-
ings of experts, prepare guide-
lines, and organize training work-
shops in disease endemic coun-
tries run by experts, in order to
support training in good prac-
tices, produce guidelines to good
practices, and help in implemen-
tation of these guidelines. The
workshops have been jointly
sponsored by TDR and its indus-
trial partners [see list].TDR’s op-
erational capability in forming
global partnerships between
public and private sectors has
been important in this work.
TDR has also set up monitoring
systems for clinical trials and has
thoroughly trained clinical moni-
tors in disease endemic countries
around the world.
Following initial GLP workshops
in the different regions, the train-
ing has become self-replicating.
Some of the original participants
have conducted similar work-
shops in their home countries to
help build up the needed capaci-
ty for conducting preclinical trials
according to good practices.
TDR has developed guidelines
(standard operating procedures)
for clinical investigators, a GLP
training manual, and is developing
a GLP handbook to be used as a
reference quality document in
disease endemic countries. As a
spin-off, a document to be used
in areas of research that are not
currently regulated (e.g. basic re-
search, discovery studies, proof-
of-principle studies, studies to es-
tablish pharmacodynamics effect
and mechanisms of action) is also
being developed by TDR.
Demand for the good practice
and ethics guidelines from the
TDR documentation center has
been brisk. News of the GLP
workshops, in particular, led to a
significant amount of interest –
judged by number of enquiries
from interested readers of the
TDR newsletter. As well, the
ethics guidelines have been wide-
ly distributed;within six months of
publication they were available in
ten languages (English, French,
German, Laotian, Filipino, Russian,
Spanish,Thai,Turkish,Vietnamese),
the translations having been fi-
nanced by various intergovern-
mental agencies, governments
and industry.
Another result of the interest in
ethics issues was that, to foster
improved understanding and im-
plementation of ethical review of
biomedical research, different fo-
ra have been set up: the Forum
on Ethics Committees in Asia and
Western Pacific (FERCAP) coun-
tries, Foro Latino Americano de
Comités de Ética in investigación
en Salud (Latin American Forum
of Ethics Committees in Health
Research - FLACEIS), Pan African
Bioethics Initiative (PABIN).
An annual course in research
ethics is now being offered by
Thammasat University,Thailand,as
part of its regular activities. This
will enable Masters and PhD
training in research ethics.
What were the results?
What was 
TDR’s role?
Partners
• Joint United Nations
Programme on HIV/AIDS
(UNAIDS)
• The pharmaceutical 
industry (including Aventis
Pasteur; SmithKline
Beecham Biologicals; 
ASTA Medica)
• Ministry of Public Health,
Thailand
• Organisation for Economic
Cooperation and
Development (OECD)
• Regulatory authorities
(IKS, Intercantonal 
Office for the Control of
Medicines, Switzerland;
FDA, Food & Drug
Administration, USA)
• Scientists from disease
endemic countries
his/her consent to take part in the
trial - presents one of the biggest
difficulties in conducting clinical
trials in developing countries. In
fact, few patients can fully under-
stand all the details about the
study they are participating in,and
careful review by the ethics com-
mittee is one of the most effec-
tive measures for this.
TDR became involved in the
transfer of good practices be-
cause of its comparative advan-
tage of being able to draw on the
expertise of the global scientific
community in both public and pri-
vate sectors. Using this to advan-
tage,the TDR guidelines were de-
veloped in partnership with the
world’s best experts in drug de-
velopment. The good practice
guidelines fulfil the need for qual-
ity control in research.
 LINES, INSTRUMENTS AND ADVICEIntroduction  
1 Gwatkin, D.R. and Guillot M. The burden of disease
among the global poor. Washington, The Global Forum for
Health Research and the World Bank, 1999
Transformation of a mosquito  
TDR (1991) Report of the meeting ‘Prospects for malaria
control by genetic manipulation of its vectors’.
TDR/BCV/MAL-ENT/91.3
Balter, M. (1999) Gene sequencers target malaria mosqui-
to. Science,  Jul 23;285(5427):508-9. 
Catteruccia, F. et al. (2000) Stable germline transforma-
tion of the malaria mosquito Anopheles stephensi. Nature
405 (6789): 959-962, 
Parasite genome  
1 Johnston, D.A. et. al. (1999) Genomics and the biology
of parasites BioEssays 21, 131 – 147. John Wiley & Sons,
Inc.
New drugs brought to registration  
1 Pécoul, B. et. al. (1999) Access to essential drugs in
poor countries: A lost battle? Journal of the American
Medical Association, 281(4): 361-367 
Xiao, S. et al. (2000) Preventive effect of artemether in
experimental animals infected with Schistosoma mansoni.
Parasitology International, 49: 19-24  
Andrade, A.L.S. et. al. (1996) Randomized trial of efficacy
of benznidazole in treatment of early Trypanosoma cruzi
infection. The Lancet, 348: 1407-1413 
Politi, C. et. al. (1995) Cost-effectiveness analysis of
alternative treatments of African gambiense trypanosomi-
asis in Uganda. Health Economics, 4: 273-287
Reich. M.R. (2000) The global drug gap. Science, 
287: 1979-1981.
Getting drugs into wide control use
Pécoul, B. et. al. (1999) Access to essential drugs in poor
countries: A lost battle? Journal of the American Medical
Association, 281(4): 361-367 
Reich. M.R. (2000) The global drug gap. Science, 287:
1979-1981.
Insecticide-treated nets     
Lengeler, C., Cattani, J., de Savigny, D. eds. (1996) Net
gain: a new method for preventing malaria deaths.
IDRC/TDR. ISBN 0-88936-792-2
Unit-dose antimalarial packs     
1 WHO (1993). Implementation of the global malaria con-
trol strategy, Geneva, Technical Report Series, No. 839.
2 TDR (1994) Treatment seeking for malaria: A review and
suggestions for future research. Social and Economic
Research in Tropical Diseases Resource Paper No.2.
(TDR/SER/RP/94.1).
Partnerships in science
Malaria research: an audit of international activity. Unit
for Policy Research in Science and Medicine, The Wellcome
Trust, London. (1996)  
Michaud, C. (1998) TDR’s impact on science: a bibliometric
study. Third External Review of TDR, Reference document
2, (TDR/ER/RD/98.2) 
Strengthening health research in the developing world:
malaria research capacity in Africa. The Wellcome Trust for
the Multilateral Initiative on Malaria, London, (1999).
Schistosomiasis control capacity in China    
Yuan, H.C., et.al. (2000) The 1992-1999 World Bank
Schistosomiasis Research Initiative in China: Outcome and
perspectives. Parasitol. Int. 49(3):195-207
Guidelines to good practices   
TDR (2000) Operational guidelines for ethics committees
that review biomedical research. (TDR/PRD/ETHICS/2000.1)
TDR (2000) Standard operating procedures for clinical
investigators. (TDR/TDP/SOP/99.1)
TDR (2000) Good laboratory practice training manual.
(TDR/PRD/GLP/00.2)
ReferencesWHO/TDR
Avenue Appia 20
1211 Geneva 27
Switzerland
Tel: (+41) 22-791-3725
Fax: (+41) 22-791-4854
E-mail: tdr@who.int
Web: www.who.int/tdr